

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

MDA-MB-231/Luciferase-2A-RFP

RRID:CVCL_YZ80

Type: Cell Line

Proper Citation

RRID:CVCL_YZ80

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_YZ80

Proper Citation: RRID:CVCL_YZ80

Description: Cell line MDA-MB-231/Luciferase-2A-RFP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Comments: Characteristics: Transduced by lentivirus with a suCMV-Luc-2A-RFP-RSV-Bsr construct (GenTarget=SC041)., Population: Caucasian., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-231/Luciferase-2A-RFP

Synonyms: MDA-MB-231 / Luciferase & RFP, MDA-MB-231 / Luc-RFP

Cross References: cancercellines:CVCL_YZ80, Wikidata:Q98127127

ID: CVCL_YZ80

Hierarchy: cvcl_0062

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260905T181122+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-231/Luciferase-2A-RFP.

No alerts have been found for MDA-MB-231/Luciferase-2A-RFP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Varadkar T, et al. (2026) Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment. Cell reports. Medicine, 102934.

Zhou Z, et al. (2026) Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy. Cancer research communications, 6(4), 898.

Varadkar T, et al. (2025) Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer. Journal of experimental & clinical cancer research : CR, 44(1), 328.

Chen K, et al. (2024) mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer. Cancer research, 84(23), 4049.